Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
about
"Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathyNovel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretinPreclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis.Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathyEarly intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathyVitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report.Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years.Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.Molecular pathogenesis of human amyloidosis: Lessons from β2 -microglobulin-related amyloidosis.Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses.Advances in proteomic study of cardiac amyloidosis: progress and potential.Current and future treatment of amyloid diseases.Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.Iatrogenic amyloid polyneuropathy after domino liver transplantation.Late-onset Familial Amyloidotic Polyneuropathy with Bence Jones Proteinuria and Cardiomyopathy.Nucleobindin 1 binds to multiple types of pre-fibrillar amyloid and inhibits fibrillization.Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients.Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis.Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm.Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy.A Missense Variant p.Ala117Ser in the Transthyretin Gene of a Han Chinese Family with Familial Amyloid Polyneuropathy.Cognitive impairment in liver transplanted patients with transthyretin-related hereditary amyloid polyneuropathy.FRET studies of various conformational states adopted by transthyretin.Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.Systemic amyloidoses and proteomics: The state of the art.Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosisAccurate, strong, and stable reporting of choroid plexus epithelial cells in transgenic mice using a human transthyretin BAC
P2860
Q26776343-28E34D11-625F-45D8-9E3E-C7BB5F185B71Q36981504-A433DC2E-25D7-43D7-B4B8-4CEEC104A344Q36981555-6882ABBC-32EE-4055-96AB-8E4BC43BD2C8Q37420577-964F46BC-3A16-4918-AFA0-764D5661D4BBQ37713229-A6E8ED8D-8F68-406F-B641-8597003854F4Q38627765-7041A2BA-4993-4604-AFD5-9B360ADC21A2Q38652127-2200BC78-BB75-4BAA-8964-52D5BC590716Q38720600-25064762-0C50-43AD-BD44-B0F8ECAFC548Q38771098-4F87C8F1-AD57-4A17-97C3-7CC8043553A6Q38787166-B1DB3876-29E1-4552-A8DD-A9BA2DE98E20Q38809423-229DAD3C-125E-44E3-B348-FE7021F71F49Q38831388-FF0FA464-6A3C-4491-BB65-79C1FF54CAE0Q38844927-73E86F99-3EE1-4555-904E-79E27D16E3B4Q39143674-00BB475F-959E-4BE4-A122-A7A2A79B7133Q41017412-7806E104-318C-4DA3-B0F6-107050CFE5CCQ42320579-022E24FC-020D-43FE-9912-B2A2C86A7FE6Q45871914-23EB7978-AF44-4B0A-974E-017F57570351Q47361404-ACA0571E-C817-4BCA-9F2C-ED72ACDD9037Q47561760-84CC76E5-E5A0-4BF5-838C-BACDE388BA6DQ49567725-42A495BE-33A0-4E10-AE89-997DBAD11D83Q50201484-F3B92B9F-35D4-437F-9746-7C2CEB92B763Q50580473-45F8B2E3-8CCF-40A7-8255-945DB99F72D3Q51016798-296C1DFD-29B2-4857-AF2F-851A80E3A125Q51165860-6D808C8B-5D46-49DE-A1BF-7D164F9C250CQ52431943-2B654731-B031-4772-8380-EC9036AFB783Q55167558-F84A846C-FA73-4002-88EF-DE398A9E7D2EQ57299899-936318B0-4F37-4EFA-A3B2-9A9763A8AF01Q58775490-E3A64D49-A3E1-4EDF-AF63-4291282A2107
P2860
Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Transthyretin (ATTR) amyloidos ...... disease-modifying treatments.
@en
type
label
Transthyretin (ATTR) amyloidos ...... disease-modifying treatments.
@en
prefLabel
Transthyretin (ATTR) amyloidos ...... disease-modifying treatments.
@en
P2860
P356
P1476
Transthyretin (ATTR) amyloidos ...... disease-modifying treatments.
@en
P2093
Yoshiki Sekijima
P2860
P304
P356
10.1136/JNNP-2014-308724
P407
P577
2015-01-20T00:00:00Z